{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:09:41Z","timestamp":1785413381717,"version":"3.56.0"},"reference-count":35,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Numerous innovations have changed diagnosis and treatment of endometrial cancer in recent years, with molecular classification being a major factor. Limited data exist on how molecular classification changes in recurrence or metastasis and what effect this may have on therapy. This retrospective study aimed to compare the molecular classification and other histopathological parameters of the primary tumor with those of recurrence or metastasis and to discuss their implications. Methods: A total of 43 patients with primary endometrial cancer and histologically confirmed recurrence treated at the Tuebingen University Women\u2019s Hospital between January 2003 and January 2017 were identified within a cohort of 964 cases. Immunohistochemistry for mismatch-repair status, estrogen receptor, p53 and L1CAM, as well as next-generation sequencing of the POLE genes were performed. Further histopathological and clinical data were collected and statistical analyses were performed. Results: No POLE-mutated patients were found. A higher proportion of high-grade tumors was observed in the recurrence (30% vs. 46%). All p53-mutated patients remained p53-mutated, while a changed molecular profile of the NSMP and MMRd subtypes was observed in nine patients (21%). L1CAM remained stable in 70% of the patients. A change in molecular profile was not associated with altered prognosis. Conclusions: Our study underlines the importance of additional histopathological analysis in case of recurrence or metastasis for individualized therapy planning. Further studies with larger case numbers are necessary to validate our findings.<\/jats:p>","DOI":"10.3390\/cancers18152454","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:38:54Z","timestamp":1785411534000},"page":"2454","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Molecular Profile Changes and Other Histopathological Parameters on Endometrial Cancer Recurrence"],"prefix":"10.3390","volume":"18","author":[{"given":"Robert","family":"Rottscholl","sequence":"first","affiliation":[{"name":"Institute of Pathology and Neuropathology, Tuebingen University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Winkelmann","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s Health, Tuebingen University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Fritz","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s Health, Tuebingen University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Gassenmaier","sequence":"additional","affiliation":[{"name":"Institute of Pathology and Neuropathology, Tuebingen University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Goetting","sequence":"additional","affiliation":[{"name":"Institute of Pathology and Neuropathology, Tuebingen University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0103-6059","authenticated-orcid":false,"given":"Annette","family":"Staebler","sequence":"additional","affiliation":[{"name":"Institute of Pathology and Neuropathology, Tuebingen University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Simma","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s Health, Tuebingen University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1690-5464","authenticated-orcid":false,"given":"Sascha","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s Health, Tuebingen University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitt","family":"Schoenfisch","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s Health, Tuebingen University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kommoss","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Diak Klinikum Landkreis Schwaebisch Hall, 74523 Schwaebisch Hall, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8588-1094","authenticated-orcid":false,"given":"Sara Y.","family":"Brucker","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s Health, Tuebingen University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1227-1118","authenticated-orcid":false,"given":"Andreas D.","family":"Hartkopf","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s Health, Tuebingen University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3059-7595","authenticated-orcid":false,"given":"Christina B.","family":"Walter","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s Health, Tuebingen University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/GRF.0b013e318218c6d1","article-title":"Recurrent Endometrial Cancer","volume":"54","author":"Boruta","year":"2011","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network, and Levine, D.A. (2013). Integrated Genomic Characterization of Endometrial Carcinoma. Nature, 497, 67\u201373.","DOI":"10.1038\/nature12113"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP Guidelines for the Management of Patients with Endometrial Carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/jnci\/djt144","article-title":"L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation","volume":"105","author":"Zeimet","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2025.08.031","article-title":"Distinct Clinical Outcomes According to Molecular Subgroups in Relapsed Endometrial Carcinoma: A Cohort Study","volume":"201","author":"Loukovaara","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1097\/PAS.0000000000002308","article-title":"Histologic and Molecular Type Changes in Endometrial Cancer Recurrences in Comparison With Their Corresponding Primary Tumors","volume":"48","author":"Muriel","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/his.15232","article-title":"Molecular Classification of Metastatic and Recurrent Endometrial Endometrioid Carcinoma: Prognostic Relevance among Low- and High-Stage Tumours","volume":"85","author":"McHenry","year":"2024","journal-title":"Histopathology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Volmer, L.L., Grube, M., Rohner, A., McAlpine, J.N., Talhouk, A., Lum, A., Matovina, S., Kommoss, S., Staebler, A., and Brucker, S.Y. (2024). Prognostic Significance of Disseminated Tumor Cells in Bone Marrow for Endometrial Carcinoma Patients. J. Clin. Med., 13.","DOI":"10.3390\/jcm13154489"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s11864-024-01180-w","article-title":"Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies","volume":"25","author":"Pomerantz","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s00432-017-2474-7","article-title":"Disseminated Tumor Cells Are Not Associated with Established Risk Factors, L1CAM Immunoreactivity and Outcome in Endometrial Carcinoma","volume":"143","author":"Kommoss","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_12","unstructured":"(2026, February 04). Available online: https:\/\/Register.Awmf.Org\/Assets\/Guidelines\/032-034OLl_S3_Endometriumkarzinom_2022-09.Pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final Validation of the ProMisE Molecular Classifier for Endometrial Carcinoma in a Large Population-Based Case Series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A Clinically Applicable Molecular-Based Classification for Endometrial Cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2016.07.090","article-title":"Molecular Classification of Endometrial Carcinoma on Diagnostic Specimens Is Highly Concordant with Final Hysterectomy: Earlier Prognostic Information to Guide Treatment","volume":"143","author":"Talhouk","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: A Simple, Genomics-Based Clinical Classifier for Endometrial Cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00432-016-2276-3","article-title":"L1CAM: Amending the \u201cLow-Risk\u201d Category in Endometrial Carcinoma","volume":"143","author":"Kommoss","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_18","unstructured":"WHO (2025). Global Cancer Observatory 2025, WHO."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1016\/j.ejca.2010.07.052","article-title":"Interpreting the Epidemiological Evidence Linking Obesity and Cancer: A Framework for Population-Attributable Risk Estimations in Europe","volume":"46","author":"Renehan","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/1471-0528.13717","article-title":"Modelling Body Mass Index and Endometrial Cancer Risk in a Pooled-Analysis of Three Case-Control Studies","volume":"123","author":"Rota","year":"2016","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"109750","DOI":"10.1016\/j.ejso.2025.109750","article-title":"SLYMEC II Study: Overall Survival Analysis of the Impact of LVSI in Apparent Early Stage Endometrioid Endometrial Cancer","volume":"51","author":"Mauro","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1CAM Further Stratifies Endometrial Carcinoma Patients with No Specific Molecular Risk Profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/IGC.0000000000000609","article-title":"ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-Up","volume":"26","author":"Colombo","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO Staging of Endometrial Cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO\u2013ESTRO\u2013ESP Guidelines for the Management of Patients with Endometrial Carcinoma: Update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab Plus Carboplatin\/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"ASTEC Study Group, Kitchener, H., Swart, A.M.C., Qian, Q., Amos, C., and Parmar, M.K.B. (2009). Efficacy of Systematic Pelvic Lymphadenectomy in Endometrial Cancer (MRC ASTEC Trial): A Randomised Study. Lancet, 373, 125\u2013136.","DOI":"10.1016\/S0140-6736(08)61766-3"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0140-6736(09)62002-X","article-title":"Survival Effect of Para-Aortic Lymphadenectomy in Endometrial Cancer (SEPAL Study): A Retrospective Cohort Analysis","volume":"375","author":"Todo","year":"2010","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Li, Y., Bian, Y., Wang, K., and Wan, X.-P. (2019). POLE Mutations Improve the Prognosis of Endometrial Cancer via Regulating Cellular Metabolism through AMF\/AMFR Signal Transduction. BMC Med. Genet., 20.","DOI":"10.1186\/s12881-019-0936-2"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PGP.0000000000001112","article-title":"Clinicopathological and Molecular Characterization of High Grade Endometrial Carcinomas of No Specific Molecular Profile (NSMP) Stratified by ER Status","volume":"45","author":"Timmermans","year":"2025","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ghafoor, S., Garcia, E., Jay, D.J., and Persad, S. (2025). Molecular Mechanisms Regulating Epithelial Mesenchymal Transition (EMT) to Promote Cancer Progression. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094364"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1476-4598-13-223","article-title":"Molecular Profiling of Circulating Tumor Cells Links Plasticity to the Metastatic Process in Endometrial Cancer","volume":"13","author":"Madissoo","year":"2014","journal-title":"Mol. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2454\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:43:43Z","timestamp":1785411823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":35,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152454"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152454","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}